Epilepsy & Behavior xxx (2018) xxx–xxx

Contents lists available at ScienceDirect

Epilepsy & Behavior

journal homepage: www.elsevier.com/locate/yebeh

Brief Communication

Eslicarbazepine acetate as a replacement for levetiracetam in people with epilepsy developing behavioral adverse events

Virupakshi Jalihal [a], Rohit Shankar [b,c,*], William Henley [c], Mary Parrett [d], Phil Tittensor [e], Brendan N. McLean [d], Ammad Ahmed [f], Josemir W. Sander [g,h,i]

[a] Ramaiah Medical College and Hospitals, Bengaluru, Karnataka 560054, India
[b] Cornwall Partnership NHS Foundation Trust, Threemilestone Industrial Estate, Truro TR4 9LD, UK
[c] Exeter Medical School, Knowledge Spa, Royal Cornwall Hospital, Truro, Cornwall TR1 3HD, UK
[d] Royal Cornwall Hospital, Truro, Cornwall TR1 3LJ, UK
[e] Royal Wolverhampton NHS Trust, UK
[f] Bial Pharma Ltd., Admiral House, Windsor SL4 3BL, UK
[g] NIHR University College London Hospitals Biomedical Research Centre, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK
[h] Chalfont Centre for Epilepsy, Chalfont St Peter, Buckinghamshire SL9 0RJ, UK
[i] Stichting Epilepsie Instellingen Nederland (SEIN), Achterweg 5, 2103 SW Heemstede, Netherlands

ARTICLE INFO

Article history:
Received 13 November 2017
Revised 16 January 2018
Accepted 17 January 2018
Available online xxxx

Keywords:
Eslicarbazepine
Levetiracetam
Psychiatric side effects
Behavior

ABSTRACT

Background: Psychiatric and behavioral side effects (PBSEs) are a major cause of antiepileptic drug (AED) withdrawal. Levetiracetam (LEV) is a recognized first-line AED with good seizure outcomes but recognized with PBSEs. Eslicarbazepine (ESL) is considered to function similarly to an active metabolite of the commonly used carbamazepine (CBZ). Carbamazepine is used as psychotropic medication to assist in various psychiatric illnesses such as mood disorders, aggression, and anxiety.
Aim: The aim was to evaluate the psychiatric profile of ESL in people who had LEV withdrawn due to PBSEs in routine clinical practice to see if ESL can be used as a possible alternative to LEV.
Methods: A retrospective observational review was conducted in two UK epilepsy centers looking at all cases exposed to ESL since its licensing in 2010. The ESL group was all patients with treatment-resistant epilepsy who developed intolerable PBSEs to LEV, subsequently trialed on ESL. The ESL group was matched to a group who tolerated LEV without intolerable PBSEs. Psychiatric disorders were identified from case notes. The Hamilton Depression Scale (HAM-D) was used to outcome change in mood. Clinical diagnoses of a mental disorder were compared between groups using the Fisher's exact test. Group differences in HAM-D scores were assessed using the independent samples *t*-test (alpha = 0.05).
Results: The total number of people with active epilepsy in the two centers was 2142 of whom 46 had been exposed to ESL. Twenty-six had previous exposure to LEV and had intolerable PBSEs who were matched to a person tolerating LEV. There was no statistical differences in the two groups for mental disorders including mood as measured by HAM-D (Chi-square test: $p = 0.28$).
Conclusion: The ESL was well tolerated and did not produce significant PBSEs in those who had PBSEs with LEV leading to withdrawal of the drug. Though numbers were small, the findings suggest that ESL could be a treatment option in those who develop PBSEs with LEV and possibly other AEDs.

1. Background

Epilepsy is a neurological condition with an enduring predisposition to generate seizures and is associated with cognitive, psychological, and social issues [1]. Neuropsychiatric disorders are also more prevalent in people with epilepsy than in the general population [2,3]. There is, however, still ambiguity as to whether these comorbidities are the result of a direct link such as a genetic predisposition or structural cause leading to seizures and psychiatric problems or if seizures over time lead to psychiatric symptoms [4].

Treatment strategies in epilepsy need to be tailored to the individual and in particular, clinicians when choosing the appropriate antiepileptic drug (AED) medication need to pay attention not only to seizure patterns but also to a number of different parameters such as age, gender, comorbidities, and cognitive state.

* Corresponding author at: Chy Govenck, Threemilestone Industrial Estate, Truro, Cornwall TR4 9LD, UK.
E-mail address: Rohit.shankar@nhs.net (R. Shankar).

https://doi.org/10.1016/j.yebeh.2018.01.020

Up to 75% of people with epilepsy may at some point have mental health issues. Antiepileptic drugs also have the potential to impact on mental health and cognition [5,6], and treatment with some AEDs is associated with the occurrence of psychiatric and behavioral side effects (PBSEs) while other may have beneficial psychotropic effects [7–10]. The PBSEs are often overlooked in epilepsy management and, withdrawal of an AED occurs only if the impact of these symptoms is significant and usually a risk to self or others.

Understanding psychotropic effects of (AEDs) is crucial but knowledge is limited. Carbamazepine (CBZ)-purported mode of action is via the modulation of voltage-sensitive sodium channels. Apart from antiepileptic action, CBZ is also used as a mood stabilizer and has proven efficacy in affective disorders. Oxcarbazepine (OXB) is structurally related to CBZ and is a prodrug that is converted into licarbazepine. The active form licarbazepine is the S enantiomer, known as eslicarbazepine (ESL). The presumed mechanism of action is as for CBZ. Conversely, OXB has never been proven to work as a mood stabilizer. In view of similarities of the postulated mechanism of action but a better tolerability profile, OXB has been used "off label" in mood management.

Levetiracetam (LEV), a commonly prescribed AED in the UK, is associated with PBSEs including irritability, depression, and anxiety [9,11]. A study suggested that PBSEs occurred in around 17% of people exposed to commonly used AEDs. Nearly 1 in 5 study participants on LEV reported PBSEs to LEV. However for CBZ the reported PBSEs were significantly lower [11]. The ESL did not figure in this study. Another study suggested that PBSEs with ESL were <2.5%. While side effects such as irritability, anxiety, and aggressive behavior have been associated with other AEDs, rates of aggression and agitation were comparable between ESL and placebo [12].

2. Aim

The aim was to evaluate the psychiatric profile of ESL in people who had LEV withdrawn due to perceived PBSEs in routine clinical practice.

3. Material and methods

3.1. ESL group (cases)

The study design was a retrospective case note review of those who satisfied the International League Against Epilepsy (ILAE) criteria of drug-resistant epilepsy [13] in two UK epilepsy secondary care centers (Cornwall and Stafford). All adults treated with ESL between 2010, when it was initially licensed, and 2016 were identified. Reasons for stopping ESL were established in those that came off it. In this subgroup, those exposed to LEV were identified and we ascertained if they were still continuing on LEV, and for those who had LEV withdrawn causes were established for the withdrawal. The final ESL group was of those who had ESL introduced after LEV withdrawal due to PBSEs.

3.2. LEV group

The LEV group was those on LEV who did not have PBSEs or if these were not severe enough to lead to discontinuation of the drug. For each individual in the ESL group, another on LEV from either center was selected as a match. Individuals were matched for clinical and demographic characteristics and time of exposure to LEV using a formal matching algorithm. It was ensured that the selected people were not on monotherapy when LEV was started.

3.3. Characteristics and evaluation of ESL and LEV groups

Demographic and clinical characteristics including etiology, seizure types, epileptic syndrome, seizure frequency, and AEDs were obtained for all. Clinical records including primary care profiles of all subjects were checked for history and type of diagnosed psychiatric disorders and alcohol problems. This included both pre- and posttreatment of ESL or LEV. Seizure response was defined as a change of seizure frequency of at least 50% vs baseline over an observation interval of 3 months. Of the major mental disorders, presentations such as psychosis or mania would be clinically recognized. Some individuals had more than one diagnoses but only the most significant diagnosis was taken. Only people who had taken ESL or LEV for over 6 months were included into the final ESL and LEV groups as this was felt adequate to achieve any dose titrations needed and reflect any identifiable associations of emergent psychiatric side effects. The ESL and LEV group participants received a Hamilton Depression Scale (HAM-D) to screen for depressive symptoms. The HAM-D was administered at the time of the last clinical review prior data collection to all participants of the project and was done posttreatment.

It is recognized that the HAM-D is a screening instrument. The HAM-D has a Sensitivity of 86.4% and Specificity of 92.2% to pick up depression. The internal consistency of the HAM-D is reported to be 0.76–0.92, and the inter-rater reliability on HAM-D is 0.87–0.95. It was felt that a recognized scale to help provide structured and objective feedback of the two groups would avoid clinical ambiguity around diagnosis of depression. Further, in recognition that there might be ambivalence around scores where HAM-D is in the range of screening for mild depression, normal–mild scores were taken as one cohort unlikely to have clinical depression and moderate–severe scores as representative of high likelihood of clinical depression.

3.4. Statistical analysis

We used descriptive statistics to assess frequencies and distributions. Clinical diagnoses of a mental disorder, alcohol misuse/dependence, and other categorical variables both pre- and posttreatment were compared between groups using Fisher's exact test. Group differences in HAM-D scores and other quantitative variables, including age, seizure frequency, and use of AEDs, were assessed using the independent samples *t*-test. The level of statistical significance was set at alpha = 0.05.

The study was approved as a clinical audit to ascertain PBSEs and potential benefits of ESL.

4. Results

The total number of people with active epilepsy in the two centers was 2142 of whom 46 had been exposed to ESL. Two had withdrawn ESL before 6 months due to nonpsychiatric effects (dizziness and nausea). A further three were withdrawn due to perceived lack of effect. Of the 41 remaining in the ESL group, three were coprescribed LEV, and thus, excluded. Twenty-six of the remaining 38 in the ESL group had previous exposure to LEV. The study design results are provided in Fig. 1.

The PBSEs which led to withdrawal of LEV included one drug-induced psychosis, six for hypomania, 18 for aggressive behavior and other personality changes such as agitation, anger, and hostility, one for personality disorder worsening, four for anxiety disorders & panic disorders, and one each for clinical depression, Post Traumatic Stress Disorder (PTSD), and depersonalization, respectively. These people subsequently received ESL (the ESL group) and tolerated it. Though all 26 had a noticeable adverse mental state change, only 10 had the symptom cluster for a diagnosable clinical psychiatric disorder pretreatment with ESL.

Each of the 26 people on ESL was matched with a person on LEV. Generalized tonic–clonic seizures (GTCS) were matched to 22 cases (85%) with 4 cases matched to focal seizures.

Demographic and baseline clinical detail summary for both the ESL and LEV group are provided in Table 1. Patients on LEV had a lower mean seizure frequency and number of AEDs used during the pretreatment period than the patients on ESL ($p < 0.01$). Table 2 provides

Please cite this article as: Jalihal V, et al, Eslicarbazepine acetate as a replacement for levetiracetam in people with epilepsy developing behavioral adverse events, Epilepsy Behav (2018), https://doi.org/10.1016/j.yebeh.2018.01.020